A Vaccine schedule refers to the recommended timeline and sequence of vaccinations for individuals of all ages to ensure optimal protection against vaccine-preventable diseases. These schedules are developed by national and international public health authorities based on scientific evidence, disease prevalence, and immunization goals. The vaccine schedule typically starts during infancy and continues throughout adulthood, with specific vaccines recommended at different ages and stages of life. During infancy and early childhood, the vaccine schedule includes vaccines to protect against diseases such as measles, mumps, rubella, polio, diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b (Hib), pneumococcal disease, and rotavirus. These vaccines are administered in multiple doses at specific intervals to ensure adequate immunity and protection.
As children grow older, additional vaccines may be recommended, including those for varicella (chickenpox), hepatitis A, meningococcal disease, and human papillomavirus (HPV). Booster doses of certain vaccines, such as tetanus, diphtheria, and pertussis (Tdap), may also be required during adolescence to maintain immunity. In adulthood, the vaccine schedule may include vaccines for influenza (flu), pneumococcal disease, shingles (herpes zoster), and tetanus, diphtheria, and pertussis (Tdap). Vaccines for specific populations, such as healthcare workers, travelers, and individuals with certain medical conditions, may also be recommended based on individual risk factors and exposure.
The vaccine schedule is continuously updated and revised to reflect changes in disease epidemiology, vaccine availability, and emerging infectious threats. For example, new vaccines may be added to the schedule as they become available, while recommendations for existing vaccines may be modified based on new scientific evidence or changes in disease prevalence. Adherence to the recommended vaccine schedule is essential for achieving and maintaining high vaccine coverage rates within populations, which is critical for establishing herd immunity and preventing outbreaks of vaccine-preventable diseases. Public health campaigns and healthcare providers play a crucial role in educating individuals and families about the importance of vaccination and ensuring timely administration of vaccines according to the schedule.
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey